http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017509322-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-1307 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-38 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0658 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-592 |
| filingDate | 2015-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017509322-A |
| titleOfInvention | Differentiation of differentiated cells |
| abstract | The present invention is a method for transdifferentiating differentiated cells, comprising contacting at least one element (i) and at least one element (ii) with the cell, wherein the element (i) (A) a polypeptide comprising at least one domain selected from the group consisting of a BH1 domain, a BH2 domain, a BH3 domain and a BH4 domain; (b) an amino acid sequence of a wild type or a fragment thereof of a Bcl-2 family member A polypeptide comprising or consisting of said amino acid sequence; (c) a polypeptide comprising or consisting of the amino acid sequence of a Bcl-2 family member wild type or fragment thereof, wherein said wild type or fragment thereof Said polypeptide comprising one or more point mutations as compared to (d) Bcl-2 A wild-type members of Li, human Bcl-2 (SEQ ID NO: 1 or 5), human Bcl-X L (SEQ ID NO: 6), human Bcl-w (SEQ ID NO: 7), human Mcl1 (SEQ ID NO: 8) , Human BfI1 (SEQ ID NO: 9 or 10), human Nrh (SEQ ID NO: 11), human Bcl2L1 (SEQ ID NO: 12), human DIVA (SEQ ID NO: 13), human myeloid cell leukemia sequence 1 isoform 1 (SEQ ID NO: 14), And an amino acid sequence exhibiting at least 30% sequence identity with said wild type of a member of the Bcl-2 family, preferably selected from the group consisting of human Bcl-xβ (SEQ ID NO: 15), or from said amino acid sequence Said wild type has anti-apoptotic activity; nucleic acid encoding said polypeptide, and Selected from means for increasing the amount and / or activity of a polypeptide, said element (i) improves the yield of transdifferentiated cells by at least 30% compared to when said element (i) is absent, and The element (ii) is selected from a transcription factor capable of transdifferentiating the cell, a nucleic acid encoding the transcription factor, and a means for increasing the amount and / or activity of the transcription factor in the cell Any method of therapeutically treating the human or animal body is excluded. Surprisingly, transdifferentiation is inhibited by oxidative stress. Thus, at least one element (iii) may be used instead of at least one element (i). Lipid peroxidation is reduced by element (iii), wherein element (iii) is (a) a vitamin D receptor, a functional homolog thereof, and a nucleic acid encoding the receptor or the functional homolog, (b) steroidal It is preferably selected from antioxidants, preferably calcitriol, (c) phenolic antioxidants, preferably tocopherols or tocotrienols, and (d) quinones, preferably coenzyme Q. In a second aspect, the present invention provides (a) at least one element (i) and at least one element (ii), (b) at least one element (iii) and at least one element (ii) ), Or (c) at least one element (i), at least one element (ii), and at least one element (iii). Is as defined above. Nucleic acids are preferred for element (i), element (ii) and element (iii) (a). |
| priorityDate | 2014-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 429.